PATENT CLAIM ANALYSIS

Application Number: 15744532
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["435", "007100"]

Abstract:
Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.

Claim (Index 14):
A method for the diagnosis of schizophrenia in a subject, the method comprising:\n a) contacting a blood sample obtained from a subject suspected of developing Schizophrenia with at least one compound of Formula (I) and at least one compound of Formula (Ia) and/or (Ib), in combination; b) determining the level of binding of said compounds of Formula (I), (la) and/or (Ib) to said sample; c) a level higher than the binding level of said compounds to a sample from non-schizophrenic individuals indicating that said individual has a high likelihood of having schizophrenia.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.28571
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13701177', '15039681', '15994978', '14764419', '09793146']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5604415103457843
- 35 USC 102 Novelty (BERT): 0.5085727913899133
- Combined Prediction Score: 0.5552546384501972
- Mean Citation Score: 181.942498
- Max Citation Score: 186.26022
- Similarity Product: 95.59572525698664

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test